Laekna (HKSE:02105) Accounts Receivable : HK$0.00 Mil (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Laekna Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Laekna's accounts receivables for the quarter that ended in Jun. 2024 was HK$0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Laekna's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was HK$1.43.

Laekna Accounts Receivable Historical Data

The historical data trend for Laekna's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna Accounts Receivable Chart

Laekna Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Accounts Receivable

Laekna Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Receivable	Get a 7-Day Free Trial			-	-	-	-	-

Laekna Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Laekna Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Laekna's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Laekna's accounts receivable are only considered to be worth 75% of book value:

Laekna's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(706.537	+	0.75 * 0	+	0.5 * 0	-	149.928
-	0	-	0)	/	390.100
=	1.43

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Laekna Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Laekna's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Laekna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

4U4:Germany

Address

No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203

Website

https://www.laekna.com

Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.

Executives

Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo	2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si	2101 Beneficial owner
Lu Chris Xiangyang	2501 Other
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Laekna Wonderland Limited	2101 Beneficial owner
Orbimed Advisors Iii Limited	2102 Investment manager
Orbimed Asia Partners Iii, L.p.	2102 Investment manager
Orbimed Asia Gp Iii, L.p.	2102 Investment manager
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc.	2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Liu Zeng	2201 Interest of corporation controlled by you
Ealex Llc	2101 Beneficial owner
Xie Ling	2501 Other

Laekna Headlines

No Headlines